ARC-001

Phase 1Small molecule

AArcato Laboratories, Inc.

ARC-001 is one of 5 small molecule programs targeting Third Molar. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Third MolarRecruiting

Third MolarPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Third Molar

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Phase 3

1 2

Glucophage

EMD Serono

Phase 2

1 3

ARC-001

AArcato Laboratories, Inc.

Phase 1

1 4

Arnica Montana

TThe University of Texas Health Science Center, Houston

Preclinical

1 5

Manuka Honey

TToyos Clinic

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Third Molar1 trial

A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction

Recruiting·AArcato Laboratories, Inc.·Phase 1·NCT06864884·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARC-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARC-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARC-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arcato Laboratories, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AArcato Laboratories, Inc.

ARC-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Third Molar1 trial

References

Drug Info

Quick Facts

Related News